SEC 13F Intelligence

Managers / Q3 2022 · view latest →

M28 Capital Management LP

CIK 0001807489 · 700 CANAL STREET, 1ST FLOOR, STAMFORD, CT, 06902 · 203-516-3730

Reported Value
$96M
Q3 2022
Positions
12
Filings on Record
18
2019–present window
Filed
Nov 10, 2022
original filing

Summary

M28 Capital Management LP reported $96M in U.S.-listed holdings across 12 positions for Q3 2022.

The portfolio is heavily concentrated: IVVD alone accounts for 30.2% of reported value.

Compared with Q2 2022, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+5.8%
vs prior filed quarter
Top-10 Concentration
+99.1%
share of reported value
Largest Position
+30.2%
Invivyd

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $128MQ4 ’21Q1 ’22: $109MQ2 ’22: $89MQ3 ’22: $96MQ3 ’22Q4 ’22: $105MQ1 ’23: $88MQ2 ’23: $76MQ2 ’23Q3 ’23: $87MQ4 ’23: $121MQ1 ’24: $135MQ1 ’24Q2 ’24: $77MQ3 ’24: $91MQ4 ’24: $102MQ4 ’24Q1 ’25: $73MQ2 ’25: $59MQ3 ’25: $68MQ3 ’25Q4 ’25: $138MQ1 ’26: $54Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 62.7%Other: 37.3%
  • Common Stock · 62.7% · $60M
  • Other · 37.3% · $36M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ATRAGBXATARA BIOTHERAPEUTICS INCSOLD OUT−269.3K0−$2M$0
TGTXTG THERAPEUTICS INCTRIMMED−387.4K338.8K−$1M$2M
VERVE THERAPEUTICS INCTRIMMED−90.9K87.6K+$282,000$3M
IVVDINVIVYD INCADDED+2.85M9.25M+$8M$29M
BBIOBRIDGEBIO PHARMA INCADDED+47.1K513.3K+$869,000$5M
RCKTROCKET PHARMACEUTICALS INCTRIMMED−50.0K665.9K+$776,000$11M
CURIS INCADDED+238.8K4.48M−$1M$3M
WAVE LIFE SCIENCES LTDHELD−300.0K7.98M+$2M$29M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IVVDINVIVYD INChistory →COM30.22%$29M9.25M
2WAVE LIFE SCIENCES LTDSHS30.08%$29M7.98M
3RCKTROCKET PHARMACEUTICALS INChistory →COM11.09%$11M665.9K
4STOKSTOKE THERAPEUTICS INChistory →COM7.00%$7M522.5K
5BBIOBRIDGEBIO PHARMA INChistory →COM5.33%$5M513.3K
6MRTXEURMIRATI THERAPEUTICS INChistory →COM4.46%$4M61.2K
7CURIS INCCOM NEW3.27%$3M4.48M
8VERVE THERAPEUTICS INCCOM3.14%$3M87.6K
9LEAP THERAPEUTICS INCCOM2.45%$2M2.66M
10TGTXTG THERAPEUTICS INChistory →COM2.09%$2M338.8K
11PROQR THRAPEUTICS N VSHS EURO0.78%$745,0001.00M
12NEXI1EURNEXIMMUNE INCCOM0.08%$74,000133.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$54M9May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$138M9Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M9Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$59M9Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$73M11May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$102M11Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$91M11Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M11Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$135M11May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M10Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$87M11Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$76M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$88M14May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M14Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$96M12Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$89M13Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$109M13May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$128M12Feb 11, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.